SEC Tracker
Get the app

Equillium EQ

Equillium FY 2024: revenue $41.1M, up 14%; diluted EPS −$0.23

Form
10-K
Filed
Period
Importance
Notable
Document
10-K
Exhibit 10.24
Material contract

Key figures from this report

These are the numbers Equillium reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$41.1M+14% from $36.1M in FY 202310-K income statement, on EDGAR
  2. Net income−$8.1MAgainst −$13.3M in FY 202310-K income statement, on EDGAR
  3. Diluted EPS−$0.23Against −$0.38 in FY 202310-K income statement, on EDGAR
  4. Cash and cash equivalents$18.1M−22% from $23.2M in FY 2023Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  5. Cash from operations−$19.0MAgainst −$21.8M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Equillium files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Sunshine Biopharma SBFM public float $7M, Jun 30, 2025
  2. Neuphoria Therapeutics NEUP public float $7M, Dec 31, 2025
  3. Protagenic Therapeutics, Inc.\new PTIX public float $7M, Sep 30, 2025
  4. LFTD Partners LIFD public float $6M, Jun 30, 2025
  5. GT Biopharma GTBP public float $9M, Jun 30, 2025